Moexipril in the Treatment of Mild to Moderate Essential Hypertension: Comparison with Sustained‐Release Verapamil
暂无分享,去创建一个
[1] P. Skøtt,et al. Age and the renin-angiotensin system. , 2009, Acta medica Scandinavica. Supplementum.
[2] P. Sever,et al. Non-angiotensin effects of angiotensin-converting enzyme inhibitors. , 1993, Clinical science.
[3] D. Vidt,et al. Medical intelligence drug therapy: captopril. , 1982, The New England journal of medicine.
[4] N. Hollenberg,et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. , 1980, The New England journal of medicine.
[5] J. Kelly,et al. Clinical Pharmacokinetics of the Newer ACE Inhibitors , 1990, Clinical pharmacokinetics.
[6] L. Katz,et al. Low‐Dose Captopril in Mild to Moderate Geriatric Hypertension , 1986, Journal of the American Geriatrics Society.
[7] J. R. Knill,et al. Captopril in the treatment of the elderly hypertensive patient. , 1985, Archives of internal medicine.
[8] G. Mugesh,et al. Converting-enzyme inhibitors in the treatment of hypertension. , 2011, The New England journal of medicine.
[9] L. Wilkins. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. , 1983, Archives of internal medicine.
[10] J. Reid,et al. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment , 1987, Clinical pharmacology and therapeutics.
[11] A. Salvetti. Newer ACE inhibitors. A look at the future. , 1990, Drugs.